Ann: Imugene onCARlytics Doses First Patient in IV Combination, page-158

The OASIS trial is real and treating patients and not just a mirage or management hot air expectations.
.
IMO, the photo of Yuman Fong and Leslie Chong posted the other day, confirms one of their discussions, by the Monday ASX announcement which stated : “We are pleased to enroll the first IV combination patient and further advance our OASIS trial, which combines our CD19 oncolytic virus with the already approved and marketed CD19 bispecific in patients with advanced solid cancers. While CD19 has been a powerful target for blood cancers, no such targets currently exist for solid cancers".

During the July 2023 Roadshow Yuman Fong stated that Blincyto and onCARlytics would be used in humans, 11 months later first patient dosed, well done to Yuman Fong, together with all the CD19 oncolytic virus researchers associated with the City of Hope (in particular Saul Priceman), so they can collect and evaluate the safety and efficacy of the patient in real time.
Congratulations to Leslie Chong with her dedication to the current trials and to all of the Imugene Team involved in those trials.

Regards.